SELE and acute lymphoblastic leukemia: E-selectin has been explored as a potential therapeutic target for concurrent chemotherapy in AML25, and the data we have shown here supports this and suggests that other types of leukemia, such as ALL, may also benefit from E-selectin based therapies.